MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$6,817,279
Unit: Dollar
Positive Cash Flow Breakdown
    • Stock-based compensation
    • Prepaid expenses and other curre...
    • Restricted stock issued for cons...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable
    • Payment of offering transactions...
    • Net effect of foreign currency e...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Loss on fair value of warrants over proceeds
-
-
0
-
Net loss
-7,943,587
-6,369,652
-3,628,762
-8,903,188
Stock-based compensation
723,915
650,024
810,796
646,900
Consulting and research expense for restricted shares issued
-
-
-
187,313
Restricted shares issued for consulting and research expense
-
-
618,813
-
Restricted stock issued for consulting expense
198,936
43,651
-
-
Change in fair value of warrant liability
69,829
-254,955
-253,512
-379,311
Prepaid expenses and other current assets
-264,876
-137,114
238,952
-11,443
Australia research and development incentives receivable
-
-
-80,410
-
Accounts payable
-144,773
940,877
-1,138,512
1,452,201
Accrued expenses
80,749
-458,387
-3,021,118
3,498,126
Net cash used in operating activities
-6,750,055
-5,311,328
-7,020,471
-3,486,516
Proceeds from exercise of warrants
0
-
0
572,654
Proceeds from private placement-Private Placement Offering One Twenty Twenty Five
0
-
0
0
Proceeds from private placement-Private Placement Offering Two Twenty Twenty Five
0
-
0
0
Proceeds from private placement-Private Placement Offering One Twenty Twenty Four
-
-
0
-
Proceeds from private placement-Private Placement Offering Three Twenty Twenty Five
0
-
0
0
Proceeds from private placement-Private Placement Offering Two Twenty Twenty Four
-
-
0
-
Proceeds from private placement-Private Placement Offering Four Twenty Twenty Five
0
-
0
0
Proceeds from private placement-Private Placement Offering Three Twenty Twenty Four
-
-
0
-
Proceeds from private placement-Private Placement Offering Five Twenty Twenty Five
-
-
2,253,900
-
Proceeds from private placement-Private Placement Offering Four Twenty Twenty Four
-
-
0
-
Proceeds from private placement-Private Placement Offering Six Twenty Twenty Five
-
-
736,600
-
Proceeds from private placement-Private Placement Offering Five Twenty Twenty Four
-
-
0
-
Proceeds from at-the-market offering
0
-
-
-
Proceeds from private placement-Private Placement Offering Seven Twenty Twenty Five
-
-
1,509,796
-
Proceeds from exercise of stock options
0
38,549
0
0
Proceeds from confidentially marketed public offering
0
33,008,813
420,780
3,779,251
Payment of offering transactions costs
65,000
1,995,041
118,704
498,429
Net cash provided by financing activities
-65,000
31,052,321
4,802,372
4,234,769
Net effect of foreign currency exchange on cash
-2,224
14,086
-15,606
-1,039
Net increase in cash
-6,817,279
25,755,079
-2,233,705
747,214
Cash at beginning of period
34,413,110
8,658,031
10,891,736
9,601,298
Cash at end of period
27,595,831
34,413,110
8,658,031
10,891,736
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase in cash-$6,817,279 (-1354.97%↓ Y/Y)Stock-based compensation$723,915 (-38.34%↓ Y/Y)Prepaid expenses andother current assets-$264,876 (-175.19%↓ Y/Y)Restricted stock issued forconsulting expense$198,936 Accrued expenses$80,749 (-91.94%↓ Y/Y)Change in fair value ofwarrant liability$69,829 (112.35%↑ Y/Y)Net cash used inoperating activities-$6,750,055 (19.04%↑ Y/Y)Net cash provided byfinancing activities-$65,000 (-100.73%↓ Y/Y)Net effect offoreign currency...-$2,224 (-119.46%↓ Y/Y)Canceled cashflow$1,338,305 Net loss-$7,943,587 (19.47%↑ Y/Y)Payment of offeringtransactions costs$65,000 (-82.95%↓ Y/Y)Accounts payable-$144,773 (-170.27%↓ Y/Y)

MAIA Biotechnology, Inc. (MAIA)

MAIA Biotechnology, Inc. (MAIA)